GlassScriptPhysician profile
Paul S Gulbas
NPI 1376552810
$13,736.43
in general payments reported to CMS, 2019-2025
21 companies · $1,552 in 2025
The $1,552 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,211 · 2020: $202 · 2021: $476 · 2022: $599 · 2023: $630 · 2024: $1,066 · 2025: $1,552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,248.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $8,760.00 | 2019 | |
| Abbvie INC. | $1,809.21 | 2022-2025 | |
| Nova Eye, INC. | $784.75 | 2025 | |
| Alcon Vision LLC | $435.52 | 2021-2025 | Rocklatan, Argos, Clareon Panoptix Pro |
| Aerie Pharmaceuticals, INC. | $371.81 | 2019-2021 | |
| Allergan, INC. | $299.65 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $273.99 | 2019-2022 | |
| Carl Zeiss Meditec USA, INC. | $207.31 | 2022-2025 | Veracity Surgical |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $183.56 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $151.08 | 2022-2025 | Vyzulta, Xiidra |
| Harrow Eye, LLC | $98.68 | 2024-2025 | Iheezo, Triesence |
| Johnson & Johnson Surgical Vision, INC. | $73.07 | 2022-2023 | Tecnis Iol |
| Kala Pharmaceuticals, INC. | $55.03 | 2019 | |
| Biotissue Holdings INC. | $52.07 | 2023-2024 | |
| Sun Pharmaceutical Industries INC. | $50.54 | 2019-2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $40.20 | 2024 | Xdemvy |
| Genmab U.S., INC. | $32.06 | 2023 | Tivdak |
| Rxsight INC | $26.24 | 2021-2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Oyster Point Pharma, INC. | $16.30 | 2024 | Tyrvaya |
| Eyevance Pharmaceuticals LLC | $15.36 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Gulbas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.